Company: AIBT
Filing Date: 2025-07-03
Form Type: 253G2
Source: 0001096906-25-001087
Chunk: 26

Company: AIBOTICS, INC.
Filing Date: 2025-07-03
Form: 253G2
Chunk 26
---
the “Asset Purchase Agreement”) and Intellectual Property Assignment Agreement (the “IP Assignment”) with Philon Labs, LLC (“Philon Labs”) for the acquisition of certain assets of Philon Labs including the intellectual property related to its “Phill Robot” and “Milky Way” products. On May 4, 2021, the Company changed its name from 20/20 Global, Inc. to Mycotopia Therapies, Inc. and changed its OTC Markets’ trading symbol to TPIA. On February 3, 2025, Mycotopia Therapies, Inc. changed its name to Aibotics, Inc. and changed its OTC Markets’ trading symbol to AIBT. Results of Operations and Financial Condition Three Months Ended March 31, 2025 as Compared to the Three Months Ended March 31, 2024 Sales and Cost of Sales We did have revenue and cost of revenue from operations for the three months ended March 31, 2025, of $2,183, as compared to $0 revenue and cost of revenue from operations for the three months ended March 31, 2024. Operating Expenses Operating expenses for the three months ended March 31, 2025 and 2024, consisted solely of general and administrative expenses. General and administrative expenses consisted primarily of consulting fees, stock-based compensation, board compensation, and legal and professional services. For the three months ended March 31, 2025 compared to the three months ended March 31, 2024 our general and administrative expense increased by $170,775, or 47%, from $360,872 to $531,647. The increase in general and administrative expenses was the result of increased legal & professional services of $13,371, increase in board compensation of $15,000, increase in product development expense of $119,967, increase in other business expenses of $4,333, increase in advertising & marketing of $7,081, and increase in consulting fees of $18,125. Other Expense Other expense for the three months ended March 31, 2025 and 2024 was composed of interest expense. 21 For the three months ended March 31, 2025 compared to the three months ended March 31, 2024 our interest expense decreased by $3,137, or 5%, from $65,070 to $61,933. The decrease primarily resulted from no interest expense related to debt discount amortization from the Company’s convertible